- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06771219
Uno studio di fase 1 con incremento della dose di SLV 154 in soggetti con tumori solidi metastatici
This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
A Bayesian optimal interval (BOIN) design with a target dose-limiting toxicity (DLT) rate for the maximum tolerated dose (MTD) of 27% and an estimated maximum sample size of ~70 subjects will be used to guide the dose escalation and determine the recommended dosing regimen (RDR) of SLV-154. Once the initial RDR is established in the Phase 1a portion of this study, further development in the Phase 1b expansion portion of this study will be considered in patients with specific cancers. In the Phase 1b part of this study, enrollment of each tumor-specific cohort will be performed using a Simon 2-stage optimal design.
SLV-154 will be administered intravenously (IV) in repeated 3-week cycles. Treatment will continue until progressive disease or discontinuation.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Langdon L Miller, MD
- Numero di telefono: 908-906-6471
- Email: lmiller@solvetx.com
Backup dei contatti dello studio
- Nome: Hong Ren, MD
- Numero di telefono: 425-894-2558
- Email: hren@solvetx.com
Luoghi di studio
-
-
California
-
Newport Beach, California, Stati Uniti, 92663
- Reclutamento
- Hoag Memorial Hospital Presbyterian
-
Contatto:
- Cindy Do, BSN, RN
- Numero di telefono: 949-764-4624
- Email: cindy.do@hoag.org
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110
- Reclutamento
- Washington University
-
Contatto:
- Sara Mitchum
- Numero di telefono: 314-273-8602
- Email: saram@wustl.edu
-
-
New Jersey
-
East Brunswick, New Jersey, Stati Uniti, 08816
- Reclutamento
- Astera Cancer Care
-
Contatto:
- Percy Yeung
- Numero di telefono: 732-387-3378
- Email: percy.yeung@asterahealthcare.org
-
-
New York
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- Memorial Sloan Kettering Cancer Center
-
Contatto:
- Roisin O'Cearbhaill, MD
- Numero di telefono: 646-888-4227
- Email: ocearbhr@mskcc.org
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44106
- Reclutamento
- University Hospitals Cleveland Medical Center
-
Contatto:
- Afshin Dowlati, MD
- Numero di telefono: 212-844-6031
- Email: afshin.dowlati@UHhospitals.org
-
Columbus, Ohio, Stati Uniti, 43210
- Reclutamento
- The James Outpatient Care West Center
-
Contatto:
- Adam Roan
- Numero di telefono: 614-685-0587
- Email: Adam.Roan@osumc.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19111
- Reclutamento
- Fox Chase Cancer Center
-
Contatto:
- Dajah White-Dumpson
- Numero di telefono: 215-214-1600
- Email: Dajah.White-Dumpson@fccc.edu
-
Contatto:
- Shannon Fabrie
- Numero di telefono: 215-728-3620
- Email: shannon.fabrie@fccc.edu
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- MD Anderson Cancer Center
-
Contatto:
- Rabia Khan
- Numero di telefono: 713-563-4667
- Email: RKhan@mdanderson.org
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- Oncology Consultants
-
Contatto:
- Julio Peguero, MD
- Numero di telefono: 713-600-0900
- Email: jPeguero@oncologyconsultants.com
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- Mays Cancer Center; University of Texas Health San Antonio
-
Investigatore principale:
- Daruka Mahadevan
-
Contatto:
- Daruka Mahadevan, MD
- Numero di telefono: 210-450-1000
- Email: mahadevand@uthscsa.edu
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98109
- Reclutamento
- University of Washington / Fred Hutchinson Cancer Center
-
Contatto:
- Phase 1 Clinical Trials
- Numero di telefono: 206-606-7551
- Email: phase1clinicaltrial@fredhutch.org
-
Tacoma, Washington, Stati Uniti, 98405
- Reclutamento
- Northwest Medical Specialties, PLLC
-
Contatto:
- CarrieAnn Brown
- Numero di telefono: 253-428-8700
- Email: cbrown@nwmsonline.com
-
Contatto:
- Kiersten Peart
- Numero di telefono: 253-428-8700
- Email: kpeart@nwmsonline.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Men or women (as appropriate for cancer type) of age ≥12 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Histologically or cytologically confirmed diagnosis of advanced cancer as documented in medical records.
- Presence of metastatic or recurrent locally advanced cancer.
- Presence of radiographically measurable disease.
- Prior receipt of one or more commercially available therapies that are indicated within product labelling or recommended under current guidelines as appropriate treatment for the subject's cancer (unless evolving data support application of SLV-154 in previously untreated subjects with high unmet medical need and inadequate and/or poorly tolerated treatment options).
- Availability of tumor tissue from a fresh tumor biopsy obtained by a core needle, excisional, or incisional biopsy; or punch biopsy (for cutaneous disease); or archival tumor sample from a previous biopsy.
- Availability of computed tomography (CT) or magnetic resonance imaging (MRI) of chest, abdomen, and pelvis, and/or fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT (if appropriate for tumor type) (with PET from base of the skull to mid-thigh, if performed) within 35 days before study drug administration.
- Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥1 week before the start of study drug administration.
- Adequate hematological profile.
- Adequate coagulation profile.
- Adequate hepatic profile.
- Adequate renal function.
- Negative viral serology or adequate therapy for human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection.
- For female subjects of childbearing potential, a negative serum pregnancy test.
- For female subjects of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until ≥6 months after the final dose of study therapy.
- For male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥6 months after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥12 months after administration of the final dose of study therapy.
- Willingness and ability of the subject to comply with scheduled visits, the drug administration plan, protocol-specified laboratory tests, other study procedures (including required tumor biopsy/aspirations and/or radiographic studies), and study restrictions.
- Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.
Exclusion Criteria:
- Unstable malignancy involving the central nervous system.
- Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.
- Uncontrolled ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infection) at the time of start of study therapy.
- Significant cardiovascular event or comorbidity.
- Significant screening ECG abnormalities.
- Pregnancy or breastfeeding.
- Major surgery within 3 weeks before the start of study therapy.
- Use of a strong inhibitor or inducer of CYP3A4 or CYP1A2.
- Concurrent participation in another therapeutic or imaging clinical trial.
- Other conditions likely to interfere with a subject's ability to participate in the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Dose Level 1
0.75 mg/kg |
SLV-154 |
|
Sperimentale: Dose Level 2
1.5 mg/kg |
SLV-154 |
|
Sperimentale: Dose Level 3
3.0 mg/kg |
SLV-154 |
|
Sperimentale: Dose Level 4
4.0 mg/kg |
SLV-154 |
|
Sperimentale: Dose Level 5
5.0 mg/kg |
SLV-154 |
|
Sperimentale: Dose Level 6
6.5 mg/kg |
SLV-154 |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Phase 1a: MTD and/or RDR
Lasso di tempo: Through the duration of treatment, up to approximately 18 months
|
Determination of the MTD (maximum tolerated dose) and/or RDR (recommended dosing regimen) for SLV-154. |
Through the duration of treatment, up to approximately 18 months
|
|
Phase 1b: Objective response rate (ORR)
Lasso di tempo: Through the duration of treatment, up to approximately 18 months
|
ORR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria and defined as the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR). |
Through the duration of treatment, up to approximately 18 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
SLV-154 administration
Lasso di tempo: Through the duration of treatment, up to approximately 18 months
|
SLV-154 drug administration as assessed by prescribing records |
Through the duration of treatment, up to approximately 18 months
|
|
SLV-154 Safety
Lasso di tempo: Through the duration of treatment, up to approximately 18 months
|
Collection of type, frequency, severity, timing of onset, duration, and relationship to study drug of any treatment-emergent adverse events (TEAEs); laboratory abnormalities; vital sign/oxygen saturation abnormalities; adverse electrocardiogram (ECG) findings; DLTs; serious adverse events (SAEs); adverse events of special interest (AESIs); or adverse events (AEs) leading to interruption, modification, or discontinuation of study drug administration. |
Through the duration of treatment, up to approximately 18 months
|
|
Evaluation of use of concomitant medications
Lasso di tempo: Through the duration of treatment, up to approximately 18 months
|
Type, frequency, and timing of use of supportive care and other concomitant medications |
Through the duration of treatment, up to approximately 18 months
|
|
SLV-154 Pharmacokinetics
Lasso di tempo: Varying timepoints through the duration of treatment, up to approximately 18 months
|
Evaluation of the pharmacokinetic profile of SLV-154 |
Varying timepoints through the duration of treatment, up to approximately 18 months
|
|
Immunogenicity
Lasso di tempo: Varying timepoints through the duration of treatment, up to approximately 18 months
|
Measurement of changes in titers of circulating SLV 154-reactive antibodies (as assessed using immunoassay methods) |
Varying timepoints through the duration of treatment, up to approximately 18 months
|
|
Time to Response (TTR)
Lasso di tempo: Up to approximately 36 months
|
TTR: interval from the start of study drug administration to the first documentation of objective tumor regression |
Up to approximately 36 months
|
|
Duration of Response (DOR)
Lasso di tempo: Up to approximately 36 months
|
DOR: interval from the first documentation of objective tumor regression to the earlier of the first documentation of disease progression or death from any cause |
Up to approximately 36 months
|
|
4-month progression-free survival (PFS4)
Lasso di tempo: Up to approximately 36 months
|
PFS4: proportion of subjects who are alive and have not experienced disease progression at 4 months after the start of study drug administration |
Up to approximately 36 months
|
|
6-month progression-free survival (PFS6)
Lasso di tempo: Up to approximately 36 months
|
PFS6: proportion of subjects who are alive and have not experienced disease progression at 6 months after the start of study drug administration |
Up to approximately 36 months
|
|
Time to treatment failure (TTF)
Lasso di tempo: Up to approximately 36 months
|
TTF: interval from the start of study drug administration to the earliest of the first documentation of disease progression, the permanent cessation of study drug due to an AE, or death from any cause |
Up to approximately 36 months
|
|
Overall survival (OS)
Lasso di tempo: Up to approximately 36 months
|
OS: interval from the start of study drug administration to death from any cause |
Up to approximately 36 months
|
|
Disease benefit ratio (DBR)
Lasso di tempo: Up to approximately 36 months
|
DBR: proportion of subjects who experience CR, PR, or stable disease with tumor reduction (SDTR) |
Up to approximately 36 months
|
|
Progression free survival (PFS)
Lasso di tempo: Up to approximately 36 months
|
PFS: interval from the start of study drug administration to the earlier of the first documentation of disease progression or death from any cause |
Up to approximately 36 months
|
|
Duration of disease benefit (DDB)
Lasso di tempo: Up to approximately 36 months
|
DDB: interval from the first documentation of objective tumor regression to the earlier of the first documentation of disease progression or death from any cause in subjects with disease benefit |
Up to approximately 36 months
|
|
Percent change in tumor dimensions
Lasso di tempo: Up to approximately 36 months
|
percent change from baseline in the sum of the longest diameters of non-nodal target lesions and the shortest diameters of nodal target lesions |
Up to approximately 36 months
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- SLV-154-01Tx
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Results will be presented in clinical study reports and publications. Individual participant data will not be shared with other researchers.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .